

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

SK-MEL-30

RRID:CVCL_0039

Type: Cell Line

Proper Citation

RRID:CVCL_0039

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0039

Proper Citation: RRID:CVCL_0039

Description: Cell line SK-MEL-30 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Cutaneous melanoma

Defining Citation: [PMID:978138](#), [PMID:1067619](#), [PMID:1716514](#), [PMID:3081645](#), [PMID:3473501](#), [PMID:3518877](#), [PMID:6864164](#), [PMID:6933476](#), [PMID:7175440](#), [PMID:7509835](#), [PMID:9598804](#), [PMID:10766161](#), [PMID:11668190](#), [PMID:15009714](#), [PMID:16957166](#), [PMID:20164919](#), [PMID:21725359](#), [PMID:22460905](#), [PMID:24576830](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Pigmented., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-30

Synonyms: SK-Mel-30, SK Mel 30, SKMEL-30, Sk Mel30, SKMEL30, AW-Mel

Cross References: BTO:BTO_0002133, CLO:CLO_0009045, EFO:EFO_0006488, CLDB:cl4323, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:465,

BioSample:SAMN03473251, BioSample:SAMN10988313, cancercellines:CVCL_0039, Cell_Model_Passport:SIDM00392, ChEMBL-Cells:ChEMBL3308128, ChEMBL-Targets:ChEMBL1075577, Cosmic:706090, Cosmic:721825, Cosmic:851035, Cosmic:888061, Cosmic:888834, Cosmic:909726, Cosmic:933128, Cosmic:1022283, Cosmic:1060425, Cosmic:1669146, Cosmic-CLP:909726, DepMap:ACH-000810, DSMZ:ACC-151, DSMZCellDive:ACC-151, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909726, GEO:GSM784510, GEO:GSM887586, GEO:GSM888669, GEO:GSM1670441, GEO:GSM7701406, GEO:GSM7701407, IARC_TP53:27239, LiGeA:CCL_671, LINCS_LDP:LCL-1257, PharmacDB:SKMEL30_1398_2019, PRIDE:PXD030304, Progenetix:CVCL_0039, PubChem_Cell_line:CVCL_0039, Wikidata:Q54954059

ID: CVCL_0039

Record Creation Time: 20220427T221546+0000

Record Last Update: 20260904T015653+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-30.

No alerts have been found for SK-MEL-30.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Jiao Y, et al. (2026) A Plasmonic "Lid-Off" Nanoplatfom for Spatiotemporally Controlled PA/NIR-II Dual-Modal Imaging and Cuproptosis-Based Synergistic Photothermal and Chemodynamic Therapy. Small (Weinheim an der Bergstrasse, Germany), 22(37), e73776.

Wilson HP, et al. (2026) Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma. Pigment cell & melanoma research, 39(3), e70090.

Lahmar A, et al. (2026) Ulvan from Ulva lactuca Promotes Keratinocyte Migration, Adhesion, and Photoprotection Against UVB Damage. Marine biotechnology (New York, N.Y.), 28(3).

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. Cancer cell, 43(5), 823.

Angeli C, et al. (2025) High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanoma. *Journal of experimental & clinical cancer research* : CR, 44(1), 278.

Waddell A, et al. (2024) p300 KAT Regulates SOX10 Stability and Function in Human Melanoma. *Cancer research communications*, 4(8), 1894.

Ran XB, et al. (2023) Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. *Cancer research*, 83(6), 922.

Cai W, et al. (2022) A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma. *Cancer research*, 82(14), 2625.

Su W, et al. (2022) ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. *Molecular cell*, 82(13), 2443.

Zhu J, et al. (2019) Transsulfuration Activity Can Support Cell Growth upon Extracellular Cysteine Limitation. *Cell metabolism*, 30(5), 865.